Category Archives: Legal

Best of the Blog: PharmExec's 10 Most Read Stories in 2013

Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you […]
Also posted in Advertising, Biotech, Emerging Markets, Europe, FDA, Global, Guest Blog, healthcare, IP, Market Access, People, pricing, R&D, Regulatory, Strategy, Technology | Tagged , , , , , , , , , , , , , | Leave a comment

Deep Breadth: GSK Doubles Down on COPD and Asthma

Will GSK be able to maintain its position in COPD and asthma, post Advair/Seretide? Despite a patent expiry in 2010, generic versions of Advair aren’t expected to appear on the market for two more years. It took FDA eight years to develop a blueprint for how generics manufacturers might establish an acceptable bioequivalence for Advair, […]
Also posted in Advertising, compliance, Emerging Markets, Europe, FDA, Global, R&D, Regulatory, Sales, Strategy | Tagged , , , , , , , , | Leave a comment

Liability Looms for Generic Drug Safety Labeling Changes

FDA is proposing to revise its rules to permit generic drug manufacturers to initiate safety labeling changes, and not wait until the brand company takes that action. The aim of the new policy is to inform consumers more quickly of emerging safety concerns – but it also could create confusion by allowing prescribing information to […]
Also posted in FDA, Regulatory, Safety | Tagged , , , , , , , | Leave a comment

Health Reform May Boost Illicit Drug Sales

Health plans that limit drug converge will encourage consumers to obtain medicines illegally, according to pharmacy experts. Marv Shepherd, director of the Center for Pharmacoeconomic Studies at the University of Texas College of Pharmacy and others noted at the Partnership for Safe Medicines Interchange in October in Washington that an increase in narrow health plan […]
Also posted in compliance, healthcare, Regulatory, Safety, Strategy | Tagged , , , , | Leave a comment

The Vanishing Rx Patient Assistance Programs?

by Tom Norton In the early 1990’s, during the debate over the Clinton healthcare plan, I recall sitting in an interesting meeting at my pharma company headquarters. In response to the Clinton’s charges that the industry was “price gouging,” my firm was proposing that we provide free prescription products to any patients who could not […]
Also posted in Corporate Responsibility, Guest Blog, healthcare, Market Access, Patient Communication | Tagged , , , , , , , | Leave a comment
  • Categories

  • Meta